Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
Identifieur interne : 002248 ( Main/Exploration ); précédent : 002247; suivant : 002249Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
Auteurs : Allan Lipton [États-Unis] ; Matthew R. Smith [États-Unis] ; Karim Fizazi [France] ; Alison T. Stopeck [États-Unis] ; David Henry [États-Unis] ; Janet E. Brown [Royaume-Uni] ; Neal D. Shore [États-Unis] ; Fred Saad [Canada] ; Andrew Spencer [Australie] ; Li Zhu [États-Unis] ; Douglas J. Warner [États-Unis]Source :
- Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2016.
Abstract
Bone antiresorptive agents can significantly reduce bone turnover markers (BTM) in patients with advanced cancer. We evaluated association of changes in BTMs with overall survival (OS), disease progression (DP), and disease progression in bone (DPB) in patients with advanced cancer and bone metastases following denosumab or zoledronic acid treatment.
DOI: 10.1158/1078-0432.CCR-15-3086
PubMed: 27140926
Affiliations:
- Australie, Canada, France, Royaume-Uni, États-Unis
- Californie, Caroline du Sud, Massachusetts, Pennsylvanie, État de New York
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001511
- to stream PubMed, to step Curation: 001489
- to stream PubMed, to step Checkpoint: 001489
- to stream Ncbi, to step Merge: 003503
- to stream Ncbi, to step Curation: 003503
- to stream Ncbi, to step Checkpoint: 003503
- to stream Main, to step Merge: 002247
- to stream Main, to step Curation: 002248
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.</title><author><name sortKey="Lipton, Allan" sort="Lipton, Allan" uniqKey="Lipton A" first="Allan" last="Lipton">Allan Lipton</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology/Oncology, Penn State Cancer Institute, Hershey, Pennsylvania. alipton@hmc.psu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Hematology/Oncology, Penn State Cancer Institute, Hershey</wicri:cityArea></affiliation></author><author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Division of Hematology/Oncology, Massachusetts General Hospital, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Stopeck, Alison T" sort="Stopeck, Alison T" uniqKey="Stopeck A" first="Alison T" last="Stopeck">Alison T. Stopeck</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, Stony Brook Cancer Center, Stony Brook, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Internal Medicine, Stony Brook Cancer Center, Stony Brook, New York</wicri:cityArea></affiliation></author><author><name sortKey="Henry, David" sort="Henry, David" uniqKey="Henry D" first="David" last="Henry">David Henry</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Medicine, Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Brown, Janet E" sort="Brown, Janet E" uniqKey="Brown J" first="Janet E" last="Brown">Janet E. Brown</name><affiliation wicri:level="1"><nlm:affiliation>Academic Unit of Clinical Oncology, Experimental Cancer Medicine Center, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Academic Unit of Clinical Oncology, Experimental Cancer Medicine Center, University of Sheffield, Sheffield</wicri:regionArea><wicri:noRegion>Sheffield</wicri:noRegion></affiliation></author><author><name sortKey="Shore, Neal D" sort="Shore, Neal D" uniqKey="Shore N" first="Neal D" last="Shore">Neal D. Shore</name><affiliation wicri:level="2"><nlm:affiliation>Carolina Urologic Research Center, Myrtle Beach, South Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Sud</region></placeName><wicri:cityArea>Carolina Urologic Research Center, Myrtle Beach</wicri:cityArea></affiliation></author><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, University of Montreal Hospital Centers, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Surgery, University of Montreal Hospital Centers, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Haematology, Monash University, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Clinical Haematology, Monash University, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Zhu, Li" sort="Zhu, Li" uniqKey="Zhu L" first="Li" last="Zhu">Li Zhu</name><affiliation wicri:level="2"><nlm:affiliation>Global Biostatistical Sciences, Amgen Inc., Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Global Biostatistical Sciences, Amgen Inc., Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Warner, Douglas J" sort="Warner, Douglas J" uniqKey="Warner D" first="Douglas J" last="Warner">Douglas J. Warner</name><affiliation wicri:level="2"><nlm:affiliation>Clinical Development, Amgen Inc., Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Clinical Development, Amgen Inc., Thousand Oaks</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27140926</idno><idno type="pmid">27140926</idno><idno type="doi">10.1158/1078-0432.CCR-15-3086</idno><idno type="wicri:Area/PubMed/Corpus">001511</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001511</idno><idno type="wicri:Area/PubMed/Curation">001489</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001489</idno><idno type="wicri:Area/PubMed/Checkpoint">001489</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001489</idno><idno type="wicri:Area/Ncbi/Merge">003503</idno><idno type="wicri:Area/Ncbi/Curation">003503</idno><idno type="wicri:Area/Ncbi/Checkpoint">003503</idno><idno type="wicri:doubleKey">1078-0432:2016:Lipton A:changes:in:bone</idno><idno type="wicri:Area/Main/Merge">002247</idno><idno type="wicri:Area/Main/Curation">002248</idno><idno type="wicri:Area/Main/Exploration">002248</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.</title><author><name sortKey="Lipton, Allan" sort="Lipton, Allan" uniqKey="Lipton A" first="Allan" last="Lipton">Allan Lipton</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology/Oncology, Penn State Cancer Institute, Hershey, Pennsylvania. alipton@hmc.psu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Hematology/Oncology, Penn State Cancer Institute, Hershey</wicri:cityArea></affiliation></author><author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><affiliation wicri:level="2"><nlm:affiliation>Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Division of Hematology/Oncology, Massachusetts General Hospital, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Stopeck, Alison T" sort="Stopeck, Alison T" uniqKey="Stopeck A" first="Alison T" last="Stopeck">Alison T. Stopeck</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, Stony Brook Cancer Center, Stony Brook, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Internal Medicine, Stony Brook Cancer Center, Stony Brook, New York</wicri:cityArea></affiliation></author><author><name sortKey="Henry, David" sort="Henry, David" uniqKey="Henry D" first="David" last="Henry">David Henry</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Medicine, Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Brown, Janet E" sort="Brown, Janet E" uniqKey="Brown J" first="Janet E" last="Brown">Janet E. Brown</name><affiliation wicri:level="1"><nlm:affiliation>Academic Unit of Clinical Oncology, Experimental Cancer Medicine Center, University of Sheffield, Sheffield, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Academic Unit of Clinical Oncology, Experimental Cancer Medicine Center, University of Sheffield, Sheffield</wicri:regionArea><wicri:noRegion>Sheffield</wicri:noRegion></affiliation></author><author><name sortKey="Shore, Neal D" sort="Shore, Neal D" uniqKey="Shore N" first="Neal D" last="Shore">Neal D. Shore</name><affiliation wicri:level="2"><nlm:affiliation>Carolina Urologic Research Center, Myrtle Beach, South Carolina.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Sud</region></placeName><wicri:cityArea>Carolina Urologic Research Center, Myrtle Beach</wicri:cityArea></affiliation></author><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, University of Montreal Hospital Centers, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Surgery, University of Montreal Hospital Centers, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Haematology, Monash University, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Clinical Haematology, Monash University, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Zhu, Li" sort="Zhu, Li" uniqKey="Zhu L" first="Li" last="Zhu">Li Zhu</name><affiliation wicri:level="2"><nlm:affiliation>Global Biostatistical Sciences, Amgen Inc., Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Global Biostatistical Sciences, Amgen Inc., Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Warner, Douglas J" sort="Warner, Douglas J" uniqKey="Warner D" first="Douglas J" last="Warner">Douglas J. Warner</name><affiliation wicri:level="2"><nlm:affiliation>Clinical Development, Amgen Inc., Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Clinical Development, Amgen Inc., Thousand Oaks</wicri:cityArea></affiliation></author></analytic><series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title><idno type="ISSN">1078-0432</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Bone antiresorptive agents can significantly reduce bone turnover markers (BTM) in patients with advanced cancer. We evaluated association of changes in BTMs with overall survival (OS), disease progression (DP), and disease progression in bone (DPB) in patients with advanced cancer and bone metastases following denosumab or zoledronic acid treatment.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Canada</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Californie</li><li>Caroline du Sud</li><li>Massachusetts</li><li>Pennsylvanie</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Lipton, Allan" sort="Lipton, Allan" uniqKey="Lipton A" first="Allan" last="Lipton">Allan Lipton</name></region><name sortKey="Henry, David" sort="Henry, David" uniqKey="Henry D" first="David" last="Henry">David Henry</name><name sortKey="Shore, Neal D" sort="Shore, Neal D" uniqKey="Shore N" first="Neal D" last="Shore">Neal D. Shore</name><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><name sortKey="Stopeck, Alison T" sort="Stopeck, Alison T" uniqKey="Stopeck A" first="Alison T" last="Stopeck">Alison T. Stopeck</name><name sortKey="Warner, Douglas J" sort="Warner, Douglas J" uniqKey="Warner D" first="Douglas J" last="Warner">Douglas J. Warner</name><name sortKey="Zhu, Li" sort="Zhu, Li" uniqKey="Zhu L" first="Li" last="Zhu">Li Zhu</name></country><country name="France"><noRegion><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Brown, Janet E" sort="Brown, Janet E" uniqKey="Brown J" first="Janet E" last="Brown">Janet E. Brown</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002248 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002248 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27140926
|texte= Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27140926" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |